Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) tinted gains of +5.45% (+0.61 points) to US$11.8. The volume of 0.51 Million shares climbed down over an trading activity of 519.56 Million shares. EPS ratio determined by looking at last 12 month figures is -5.1. Over the same time span, the stock marked US$32.9 as its best level and the lowest price reached was US$7.42. The corporation has a market cap of US$319.07 Million.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)’s earnings per share has been growing at a -41.5 percent rate over the past 5 year when average revenue increase was noted as -56.7 percent. The return on equity ratio or ROE stands at -106.7 percent while most common profitability ratio return on investment (ROI) was -51.1 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 99 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 1.92. 7 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Blueprint Medicines Corporation (NASDAQ:BPMC) is worth US$3.78 Billion and has recently risen 5.37% to US$86.6. The latest exchange of 1.16 Million shares is below its average trading activity of 336.13 Million shares. The day began at US$82.84 but the price moved to US$81.9 at one point during the trading and finally capitulating to a session high of US$87.36. The stock tapped a 52-week high of US$109 while the mean 12-month price target for the shares is US$100.14.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 7.77, and a price to sales ratio of 83.74. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 0%, it carries an earnings per share ratio of -4.79.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 5 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.38.